Genomic reiterated at market outperform by JMP

Genomic Health, Inc. was reiterated by JMP Securities analyst Ryan Graham at market outperform with a $19 price target. The analyst believes the Food and Drug Administration will continue to scrutinize the genetic testing industry and that Genomic has a high likelihood of winning FDA favor, perhaps becoming the industry standard bearer. Shares of the Redwood City, Calif., biotechnology company were up 1 cent, or 0.08%, at $12.09 on volume of 75,078 shares versus the three-month running average of 146,903 shares. (Nasdaq: GHDX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.